A glypican-3-derived peptide vaccine against hepatocellular carcinoma

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1448-1450

  Sawada, Yu ^a   Sakai, Mayuko ^a   Yoshikawa, Toshiaki ^a   Ofuji, Kazuya ^a   Nakatsura, Tetsuya ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Clinical trial; Cytotoxic T lymphocyte; Glypican 3; Hepatocellular carcinoma; Peptide vaccine

Indexed keywords

FREUND ADJUVANT; GLUTAMYLTYROSYLISOLEUCYLLEUCYLGLUTAMYLGLUTAMYLLEUCINE; GLYPICAN 3 DERIVED PEPTIDE VACCINE; HLA A ANTIGEN; HLA A24 ANTIGEN; PEPTIDE VACCINE; PHENYLALANYLVALYLGLYCYLGLUTAMYLPHENYLALANYLPHENYLALANYLTHREONYLASPARTYLVALINE; UNCLASSIFIED DRUG;

ADVANCED CANCER; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL TRANSFER; CELLULAR IMMUNITY; DRUG DOSE ESCALATION; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER SURGERY; NONHUMAN; NOTE; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; VACCINATION;

EID: 84873696966     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21351     Document Type: Note

References (10)

1. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306:16-25; PMID:12788060; http://dx.doi.org/10.1016/S0006-291X(03)00908-2.
2. Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, Katagiri T, et al. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 2004; 10:8630-40; PMID:15623647; http://dx.doi.org/10.1158/1078-0432.CCR-04-1177.
3. Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol 2009; 34:649-56; PMID:19212669.
4. Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009; 100:1403-7; PMID:19496787; http://dx.doi.org/10.1111/j.1349-7006.2009.01206.x.
5. Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12:2689-97; PMID:16675560; http://dx.doi.org/10.1158/1078-0432.CCR-05-2267.
6. Motomura Y, Ikuta Y, Kuronuma T, Komori H, Ito M, Tsuchihara M, et al. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int J Oncol 2008; 32:985-90; PMID:18425324.
7. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, et al. Phase I trial of glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunological evidence and potential for improving overall survival. Clin Cancer Res 2012.: http://dx.doi.org/10.1158/1078-0432.CCR-11-3044.
8. Yoshikawa T, Nakatsugawa M, Suzuki S, Shirakawa H, Nobuoka D, Sakemura N, et al. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci 2011; 102:918-25; PMID:21281401; http://dx.doi.org/10.1111/j.1349-7006.2011.01896.x.
9. Suzuki S, Yoshikawa T, Hirosawa T, Shibata K, Kikkawa F, Akatsuka Y, et al. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. Cancer Sci 2011; 102:1622-9; PMID:21668581; http://dx.doi.org/10.1111/j.1349-7006.2011.02003.x.
10. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21:233-40; PMID:19304471; http://dx.doi.org/10.1016/j.coi.2009.03.002.